314130 — Genome&Company Income Statement
0.000.00%
Last trade - 00:00- KR₩85bn
- KR₩92bn
- KR₩28bn
Annual income statement for Genome&Company, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | ARS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 151 | 451 | 14,085 | 14,296 | 27,745 |
| Cost of Revenue | |||||
| Gross Profit | 151 | 374 | 5,598 | 4,064 | 15,670 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 26,779 | 36,538 | 71,597 | 71,714 | 60,311 |
| Operating Profit | -26,629 | -36,087 | -57,512 | -57,418 | -32,566 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -31,186 | -36,004 | -58,033 | -51,855 | -28,215 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -31,186 | -36,004 | -56,950 | -50,653 | -26,850 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -30,732 | -34,117 | -51,838 | -47,466 | -20,112 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -30,732 | -34,117 | -51,838 | -47,466 | -20,112 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1,591 | -1,269 | -1,842 | -1,626 | -480 |
| Dividends per Share |